Barely Significant
← all excerpts

<i>ESR1</i> mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception.

Explor Target Antitumor Ther · 2026 · PMC13220126 · PMID 42222274

Europe PMCDOI
1
hedged sentence
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

did not reach statistical significanceP = 0.07so close (0.05 < p ≤ 0.1)
The VERITAC-2 trial results showed that in the overall (unselected) population, the PFS difference did not reach statistical significance (HR 0.83, 95% CI 0.69–1.01; P = 0.07), confirming the predictive value of ESR1 mutation status.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.